GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the second quarter of 2026 and provided a business update, highlighting continued progress toward the planned initiation of a pivotal immunobridging study for its GEO-MVA vaccine candidate. The company is pursuing an expedited regulatory pathway established through formal Scientific Advice discussions with the European Medicines Agency (EMA).
During the quarter, GeoVax advanced clinical operations planning, manufacturing preparedness, and utilization of previously manufactured cGMP clinical trial material. The company also progressed its AGE1 continuous cell-line manufacturing platform, which is intended to support future commercial-scale MVA vaccine production. Additionally, GeoVax engaged with government, public health, and biodefense stakeholders to address long-term orthopoxvirus preparedness and vaccine supply requirements.
“During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study,” said David A. Dodd, Chairman and CEO of GeoVax. “Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.”
GeoVax believes GEO-MVA is uniquely positioned to help address the need for diversified global MVA vaccine manufacturing capacity. The vaccine candidate is designed to protect against mpox and smallpox, and the pivotal study aims to demonstrate non-inferiority to an approved MVA vaccine through an immunobridging approach.
In parallel, GeoVax continues to advance its Gedeptin immuno-oncology program. Gedeptin is an investigational gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin's localized tumor-targeting mechanism may complement PD-1-based therapies, such as Merck’s Keytruda, by improving responsiveness in immunologically resistant tumors. GeoVax holds an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4.4 million for the second quarter of 2026, or $0.97 per share, compared to a net loss of $5.4 million, or $8.74 per share, in the same period of 2025. For the six months ended June 30, 2026, the net loss was $9.7 million, or $2.94 per share, compared to $10.7 million, or $19.72 per share, in the prior year. The company recognized no revenue from government contracts in the 2026 period, compared to $0.9 million in Q2 2025 and $2.5 million in the first half of 2025, which were associated with the BARDA contract for its GEO-CM04S1 COVID-19 vaccine program. In April 2025, BARDA terminated that contract for convenience.
Research and development expenses decreased to $3.1 million in Q2 2026 from $4.7 million in Q2 2025, primarily due to lower costs from discontinued BARDA activities and reduced GEO-CM04S1 clinical spending. General and administrative expenses fell to $1.3 million from $1.5 million, driven by lower investor relations consulting costs and stock-based compensation. As of June 30, 2026, GeoVax held $3.1 million in cash and cash equivalents, unchanged from year-end 2025.
In May 2026, GeoVax announced a strategic reprioritization to concentrate resources on GEO-MVA and Gedeptin, discontinuing active development of its COVID-19 vaccine candidate. The decision was not based on safety or efficacy concerns but reflected the evolving global COVID-19 vaccine market and GeoVax’s focus on programs with clearer regulatory pathways and commercialization potential.
Looking ahead, GeoVax expects to initiate the GEO-MVA pivotal immunobridging study in the fourth quarter of 2026. The company continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities.
